DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Recruiting now

Conditions studied: Transthyretin Amyloidosis With Cardiomyopathy

In brief

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Key facts

Study ID

NCT07358078

Run by

Alnylam Pharmaceuticals

People needed

2000

Starts

2026-01-09

Expected to finish

2030-10-23

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a diagnosis of ATTR-CM
• Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

You may not qualify if…

• Is enrolled in an interventional clinical trial

Where it is running

• Clinical Trial Site — Naples, Florida, United States (enrolling)
• Clinical Trial Site — Boston, Massachusetts, United States (enrolling)
• Clinical Trial Site — New Brunswick, New Jersey, United States (enrolling)
• Clinical Trial Site — Memphis, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.